PLX Quote, Financials, Valuation and Earnings

Accuray has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of -3.89%. Protalix BioTherapeutics's return on equity of -29.54% beat Accuray's return on equity of -35.94%.

Protalix BioTherapeutics has a consensus price target of --, signalling upside risk potential of 695.46%. On the other hand Accuray has an analysts' consensus of -- which suggests that it could grow by 231.98%. Given that Protalix BioTherapeutics has higher upside potential than Accuray, analysts believe Protalix BioTherapeutics is more attractive than Accuray.

Protalix BioTherapeutics has a beta of 0.741, which suggesting that the stock is 25.895% less volatile than S&P 500. In comparison Accuray has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.103%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Accuray pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $18M, which are smaller than Accuray quarterly revenues of $101.5M. Protalix BioTherapeutics's net income of $3.2M is higher than Accuray's net income of -$4M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 115.00x while Accuray's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 3.03x versus 0.41x for Accuray. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of -29.54% beat Armata Pharmaceuticals's return on equity of --.

Protalix BioTherapeutics has a consensus price target of --, signalling upside risk potential of 695.46%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 258.97%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

Protalix BioTherapeutics has a beta of 0.741, which suggesting that the stock is 25.895% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.777, suggesting its less volatile than the S&P 500 by 22.301%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $18M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Protalix BioTherapeutics's net income of $3.2M is higher than Armata Pharmaceuticals's net income of -$5.5M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 115.00x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 3.03x versus 706.46x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of -29.54% beat Perspective Therapeutics's return on equity of --.

Protalix BioTherapeutics has a consensus price target of --, signalling upside risk potential of 695.46%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Protalix BioTherapeutics has higher upside potential than Perspective Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Perspective Therapeutics.

Protalix BioTherapeutics has a beta of 0.741, which suggesting that the stock is 25.895% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $18M, which are larger than Perspective Therapeutics quarterly revenues of --. Protalix BioTherapeutics's net income of $3.2M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 115.00x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 3.03x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of 10.05%. Protalix BioTherapeutics's return on equity of -29.54% beat Electromed's return on equity of 15.62%.

Protalix BioTherapeutics has a consensus price target of --, signalling upside risk potential of 695.46%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 19.01%. Given that Protalix BioTherapeutics has higher upside potential than Electromed, analysts believe Protalix BioTherapeutics is more attractive than Electromed.

Protalix BioTherapeutics has a beta of 0.741, which suggesting that the stock is 25.895% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $18M, which are larger than Electromed quarterly revenues of $14.7M. Protalix BioTherapeutics's net income of $3.2M is higher than Electromed's net income of $1.5M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 115.00x while Electromed's PE ratio is 38.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 3.03x versus 4.33x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.